Jon Holmlund

Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer

John Nemunaitis, Jon Holmlund, Maura A. Kraynak et al. · Journal of Clinical Oncology · 1999 · 173 citations

Medicine, Oncology, Pharmacology +16

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

Luca Paoluzzi, Mithat Gönen, Jeffrey R. Gardner et al. · Blood · 2008 · 147 citations · Full text

Medicine, Cancer Biology, Oncology +8

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

Guru Sonpavde, John M. Burke, J. R. Caton et al. · Annals of Oncology · 2011 · 143 citations

Medicine, Oncology, Pharmacology +16

The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin

John W. Smith, Dan. L Longo, W. Gregory Alvord et al. · New England Journal of Medicine · 1993 · 139 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-<i>raf</i>-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)

James Stevenson, Kang-Shen Yao, Maryann Gallagher et al. · Journal of Clinical Oncology · 1999 · 131 citations

Medicine, Oncology, Pharmacology +15